Takeda Pharmaceutical Company Limited
TAK
$14.16
$0.443.21%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.63% | -30.09% | 7.52% | 37.67% | -55.27% |
| Total Depreciation and Amortization | -0.94% | -1.79% | -0.33% | 0.79% | 1.21% |
| Total Amortization of Deferred Charges | 20.80% | 20.80% | 13.61% | 13.61% | 13.61% |
| Total Other Non-Cash Items | 638.67% | 28.02% | 85.68% | -165.42% | -22.38% |
| Change in Net Operating Assets | 182.86% | 118.96% | 163.22% | -392.19% | -959.03% |
| Cash from Operations | 37.79% | 41.43% | 40.16% | -15.84% | -25.61% |
| Capital Expenditure | -2.47% | -8.34% | -9.35% | -19.53% | -18.47% |
| Sale of Property, Plant, and Equipment | -24.95% | -99.13% | -99.52% | -96.77% | 740.27% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 111.70% | 0.51% | 211.03% | 197.88% | 139.90% |
| Other Investing Activities | 46.11% | 46.27% | 69.17% | 74.08% | 72.72% |
| Cash from Investing | 30.94% | 27.02% | 56.63% | 59.47% | 59.40% |
| Total Debt Issued | 7.89% | 179.03% | 106.36% | 254.30% | 107.58% |
| Total Debt Repaid | -329.24% | -263.86% | -154.68% | -18.12% | 27.60% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -5,297.50% | -2,129.58% | 19.09% | 19.09% | 19.09% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.12% | 2.38% | 3.33% | 3.14% | 3.95% |
| Other Financing Activities | -718.44% | -24.60% | -39.09% | -13.84% | 86.91% |
| Cash from Financing | -534,540.79% | -103.83% | -61.57% | 105.19% | 100.04% |
| Foreign Exchange rate Adjustments | -212.44% | -145.49% | -55.10% | -283.62% | 67.89% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | 147.92% |
| Net Change in Cash | -193.97% | 17.97% | 145.91% | 200.37% | 230.94% |